CDI-988 / Cocrystal Pharma - LARVOL DELTA

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snowy Mountain Virus (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Cocrystal Pharma, Inc.

New P1/2 trial

CDI-988 Safety Study in Healthy Participants (clinicaltrials.gov) - P1 | N=86 | Recruiting | Sponsor: Cocrystal Pharma, Inc. | Trial completion date: Nov 2024 ➔ Apr 2025 | Trial primary completion date: Nov 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date

On the origins of SARS-CoV-2 main protease inhibitors. (PubMed, RSC Med Chem) - "In less than 3 years of research, 4 inhibitors of SARS-CoV-2-M have actually been authorized for COVID-19 treatment (nirmatrelvir, ensitrelvir, leritrelvir and simnotrelvir) and more such as EDP-235, FB-2001 and STI-1558/Olgotrelvir or five undisclosed compounds (CDI-988, ASC11, ALG-097558, QLS1128 and H-10517) are undergoing clinical trials. Since many series of covalent SARS-CoV-2-M inhibitors owe some of their origins to previous work on other proteases, we first provided a description of various inhibitors of cysteine-bearing human caspase-1 or cathepsin K, as well as inhibitors of serine proteases such as human dipeptidyl peptidase-4 or the hepatitis C protein complex NS3/4A. This is then followed by a description of the results of the approaches adopted (repurposing, structure-based and high throughput screening) to discover coronavirus main protease inhibitors."

Journal • Review • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • CASP1 • CTSK • SPECC1

CDI-988 Safety Study in Healthy Participants (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Cocrystal Pharma, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

CDI-988 Safety Study in Healthy Participants (clinicaltrials.gov) - P1 | N=56 | Not yet recruiting | Sponsor: Cocrystal Pharma, Inc.

New P1 trial